Could a pill stop snake venom? new trial tests oral drugs against antivenom
NCT ID NCT07500233
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests two oral drugs, DMPS and marimastat, to see if they can reduce the harmful effects of snake venom. 504 adults in Brazil and Ghana who have been bitten by a snake will receive either the drug, a placebo, or standard antivenom. The goal is to find a treatment that can be given quickly in rural clinics, potentially saving lives and preventing disability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DMPS (unithiol) and marimastat, taken orally
- What this could lead to
- If successful, these oral drugs could be given sooner than antivenom, potentially reducing disability and death from snakebites, especially in remote areas.
- What could go wrong
- This is an early phase 2 trial with only 504 participants. The drugs may not work as hoped, could have side effects, or may not be as effective as antivenom.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SNAKEBITE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.